Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people expect semaglutide to switch off hunger completely. Many do find their appetite drops significantly within the first few weeks, but a meaningful number still feel hungry at times, and that is entirely normal. Semaglutide is a prescription-only medicine; a prescriber assesses whether it suits you before treatment begins. What hunger looks and feels like on treatment is worth understanding before you read too much into it.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
That scenario is more common than the before-and-after stories online suggest. Semaglutide works through the GLP-1 receptor, it slows gastric emptying and sends fullness signals to the brain, which the NHS's semaglutide patient page describes clearly. But 'works' is not the same as 'works uniformly for every person at every dose'. In the early weeks, many people are still on the 0.25mg or 0.5mg starting doses, which exist primarily to let the body adjust rather than to produce the full appetite effect. If you want to understand more about why this happens, our guide on being still hungry on semaglutide covers the dose-by-dose picture in detail, including what to expect as you titrate upward.
There is also a distinction worth making between two different feelings people often conflate: physiological hunger (your stomach is genuinely empty and blood glucose is dropping) and food noise, the mental chatter, cravings and habitual urge to eat that are driven less by calories needed and more by patterns, stress, or boredom. Semaglutide tends to quiet food noise effectively for many people, but it may dull it rather than silence it, especially early in treatment.
If the hunger you're experiencing is happening at specific times (mid-morning, late evening, after exercise) that pattern often points to something practical and fixable rather than a sign the medicine isn't working.
Individual variation in response is real. Body weight, metabolic rate, how quickly someone titrates, other medications, and gut physiology all influence how much appetite suppression someone experiences. For people specifically on the branded version, our page explaining whether you feel hungry on Wegovy addresses why the experience differs so much from one person to the next. The STEP 1 trial, published in the New England Journal of Medicine, reported an average weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose, but that is an average across a large population, and individual results varied considerably around it.
Protein and fibre intake matter more on this treatment than off it. Protein is the most satiating macronutrient and helps preserve muscle mass during weight loss; fibre slows digestion further. If your meals are carbohydrate-heavy and low in both, semaglutide's effect on gastric emptying may not be enough to keep hunger at bay between meals. What you eat while on Wegovy can make a tangible difference to how full you feel, independent of the dose itself.
Hydration is another underappreciated factor. Mild dehydration can present as hunger, and if nausea is putting you off eating and drinking normally in the early weeks, a cycle of low fluid intake and increased hunger can follow. Keeping a bottle of water nearby, especially in the hours after your weekly injection, is a small habit that helps more than it sounds.
There is a difference between hunger that is manageable and reduced compared to before treatment, and hunger that is unchanged or worsening after several months at the maintenance dose. The first is common and often improves. The second is worth a clinical conversation. If you have been on the full maintenance dose of semaglutide for at least a few months and feel no meaningful reduction in appetite, your prescriber needs to know, it is part of the monitoring that should happen with any GLP-1 treatment. Some people find persistent hunger on Wegovy specifically warrants a review of whether they are on the right treatment for their physiology.
Semaglutide is also not the only licensed option for weight management. Tirzepatide (Mounjaro) works on two receptors rather than one, and for some individuals that dual action produces greater appetite suppression. Whether switching makes clinical sense is a decision for a prescriber, not something to self-direct. For an independent look at how the two treatments compare, the full Wegovy overview and the weight-loss treatments summary are good starting points before a consultation.
If you're considering starting treatment or already on it and finding that hunger is undermining progress, checking your eligibility with our prescribing team costs nothing and takes a few minutes. A clinical review, not a chatbot, looks at your answers the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.